Correlation Between Nuvectis Pharma and Insight Molecular

Can any of the company-specific risk be diversified away by investing in both Nuvectis Pharma and Insight Molecular at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nuvectis Pharma and Insight Molecular into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Nuvectis Pharma and Insight Molecular Diagnostics, you can compare the effects of market volatilities on Nuvectis Pharma and Insight Molecular and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nuvectis Pharma with a short position of Insight Molecular. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nuvectis Pharma and Insight Molecular.

Diversification Opportunities for Nuvectis Pharma and Insight Molecular

0.06

Correlation Coefficient

Nuvectis Pharma  Insight Molecular

Significant diversification

The 3 months correlation between Nuvectis and Insight is 0.06. Overlapping area represents the amount of risk that can be diversified away by holding Nuvectis Pharma and Insight Molecular Diagnostics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Insight Molecular and Nuvectis Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nuvectis Pharma are associated (or correlated) with Insight Molecular. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Insight Molecular has no effect on the direction of Nuvectis Pharma i.e., Nuvectis Pharma and Insight Molecular go up and down completely randomly.

Pair Corralation between Nuvectis Pharma and Insight Molecular

Given the investment horizon of 90 days Nuvectis Pharma is expected to generate 2.31 times less return on investment than Insight Molecular. But when comparing it to its historical volatility, Nuvectis Pharma is 1.55 times less risky than Insight Molecular. It trades about 0.16 of its potential returns per unit of risk. Insight Molecular Diagnostics is currently generating about 0.25 of returns per unit of risk over similar time horizon. If you would invest  328.00  in Insight Molecular Diagnostics on October 6, 2025 and sell it today you would earn a total of  388.00  from holding Insight Molecular Diagnostics or generate 118.29% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Nuvectis Pharma  vs.  Insight Molecular Diagnostics

Nuvectis Pharma

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Nuvectis Pharma are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak fundamental indicators, Nuvectis Pharma unveiled solid returns over the last few months and may actually be approaching a breakup point.

Insight Molecular

Risk-Adjusted Performance

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Insight Molecular Diagnostics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady fundamental indicators, Insight Molecular showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Nuvectis Pharma and Insight Molecular

The main advantage of trading using opposite Nuvectis Pharma and Insight Molecular positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nuvectis Pharma position performs unexpectedly, Insight Molecular can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Insight Molecular will offset losses from the drop in Insight Molecular's long position.

The idea behind Nuvectis Pharma and Insight Molecular Diagnostics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.